Rznomics announced on the 18th that it has been selected as ‘Top 50 Companies in excellent Technology Development for SMEs’ by Korean ‘Ministry of SMEs and Startups.’ 

The 50 Best Technology Development for SMEs is in its first year to promote innovation, quality advancement, and commercialization of excellent technology development for SMEs.

The 50 Best Technology Development for SMEs evaluates and selects 30 companies with excellent commercialization performance, including cumulative sales of technology development projects, ▲ 6 companies that achieved world-class technology in the national strategic technology field ▲ 7 companies that succeeded overcoming technology takeover and management crisis ▲ 7 innovative product companies that contributed to improving public services such as industrial safety over the past five years (2018-2023).

For its selected grant projects by the Ministry of SMEs and Startups, Rznomics has developed RNA replacement enzymes that can be used as selective and specific treatments as a new way to replace genes at the mRNA level. Based on the aforementioned development, Rznomics is selected as one of the final six companies in the national strategic technology sector in recognition of its excellence and differentiation of technology development performances, with performances such approval of the clinical trial plan (IND) of development of liver cancer gene therapy by Ministry of Food and Drug Safety and U.S. Food and Drug Administration, domestic and international patent registration, and verification of anticancer efficacy by independent administration.

Based on the same platform technology recognized, mentioned above, Rznomics has also obtained IND approval from the Ministry of Food and Drug Safety and the FDA for glioblastoma (malignant brain tumor) treatments. And Rznomics is preparing to conduct clinical trials within this year.

In addition, IND applications for the treatment of autosomal dominant formulation hereditary retinopathy, which is first pipeline of Rznomics to treat genetic rare disease currently without treatment, is also being prepared to be submitted in early 2024.

Seong-wook Lee, CEO of Rznomics, said, "I am pleased to be able to recognize Rznomics' technology for its excellence and selection as a top 50 company. We will use this opportunity to promote our technology more widely and do our best to implement Rznomics’ technology as an innovative treatment that can solve the unmet demand for rare and intractable diseases.”